HomeCompareGOVXW vs QYLD

GOVXW vs QYLD: Dividend Comparison 2026

GOVXW yields 57142.86% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GOVXW wins by $1.8137199447430393e+24M in total portfolio value
10 years
GOVXW
GOVXW
● Live price
57142.86%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8137199447430393e+24M
Annual income
$1,807,497,607,342,771,000,000,000,000,000.00
Full GOVXW calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — GOVXW vs QYLD

📍 GOVXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGOVXWQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GOVXW + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GOVXW pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GOVXW
Annual income on $10K today (after 15% tax)
$4,857,142.86/yr
After 10yr DRIP, annual income (after tax)
$1,536,372,966,241,355,200,000,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, GOVXW beats the other by $1,536,372,966,241,355,200,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GOVXW + QYLD for your $10,000?

GOVXW: 50%QYLD: 50%
100% QYLD50/50100% GOVXW
Portfolio after 10yr
$9.068599723715196e+23M
Annual income
$903,748,803,671,385,500,000,000,000,000.00/yr
Blended yield
99.66%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GOVXW buys
0
QYLD buys
0
No recent congressional trades found for GOVXW or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGOVXWQYLD
Forward yield57142.86%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.8137199447430393e+24M$25.4K
Annual income after 10y$1,807,497,607,342,771,000,000,000,000,000.00$5,659.31
Total dividends collected$1.813311652454266e+24M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: GOVXW vs QYLD ($10,000, DRIP)

YearGOVXW PortfolioGOVXW Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$5,724,986$5,714,285.71$10,352$1,192.36+$5.71MGOVXW
2$3,063,527,985$3,057,402,250.62$10,830$1,347.57+$3063.52MGOVXW
3$1,532,308,824,967$1,529,030,850,022.66$11,460$1,539.07+$1532308.81MGOVXW
4$716,394,107,906,517$714,754,537,463,802.60$12,275$1,777.84+$716394107.89MGOVXW
5$313,071,475,901,711,400$312,304,934,206,251,460.00$13,323$2,078.95+$313071475901.70MGOVXW
6$127,886,778,198,343,160,000$127,551,791,719,128,320,000.00$14,667$2,463.34+$127886778198343.14MGOVXW
7$48,831,901,813,479,680,000,000$48,695,062,960,807,450,000,000.00$16,396$2,960.57+$48831901813479680.00MGOVXW
8$17,429,423,992,127,943,000,000,000$17,377,173,857,187,520,000,000,000.00$18,631$3,612.97+$17429423992127942656.00MGOVXW
9$5,815,268,598,381,736,000,000,000,000$5,796,619,114,710,159,000,000,000,000.00$21,548$4,482.15+$5.815268598381735e+21MGOVXW
10$1,813,719,944,743,039,200,000,000,000,000$1,807,497,607,342,771,000,000,000,000,000.00$25,398$5,659.31+$1.8137199447430393e+24MGOVXW

GOVXW vs QYLD: Complete Analysis 2026

GOVXWStock

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Full GOVXW Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this GOVXW vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GOVXW vs SCHDGOVXW vs JEPIGOVXW vs OGOVXW vs KOGOVXW vs MAINGOVXW vs XYLDGOVXW vs JEPQGOVXW vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.